Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study

The Lancet Infectious Diseases
Armand AbergelVéronique Loustaud-Ratti

Abstract

Data about the response of hepatitis C virus (HCV) genotype 5 to approved and experimental treatment regimens are scarce. We assessed the efficacy and safety of combination therapy with the NS5A inhibitor ledipasvir and the NS5B polymerase inhibitor sofosbuvir in patients with HCV genotype 5. We did this open-label, multicentre, single-arm, phase 2 trial at five hospitals in France. Eligible patients were at least 18 years old and had chronic infection with HCV genotype 5, with plasma HCV RNA of at least 10,000 IU/mL. We used BLAST analyses of NS5B partial sequences to establish the genotype and subtype at screening. Patients were given a fixed-dose combination tablet of 90 mg ledipasvir and 400 mg sofosbuvir orally once per day for 12 weeks. The primary endpoint was the proportion of patients with a sustained viral response, defined as HCV RNA concentration less than 15 IU/mL at 12 weeks after the end of treatment (SVR12). We analysed efficacy and safety in all patients who received at least one dose of ledipasvir-sofosbuvir. This trial is registered with EudraCT, number 2013-003978-27, and with ClinicalTrials.gov, number NCT02081079. From March 7 to June 10, 2014, we recruited 41 patients, including 21 who were treatment naiv...Continue Reading

References

Sep 29, 2007·Alimentary Pharmacology & Therapeutics·A AbergelC Henquell
Mar 19, 2008·Epidemiology and Infection·N AntakiUNKNOWN Syrian Working Group for the Study of Viral Hepatitis
Jan 22, 2011·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Cécile HenquellJean-Luc Bailly
Mar 15, 2011·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Lisa I BackusLarry A Mole
Dec 27, 2012·JAMA : the Journal of the American Medical Association·Adriaan J van der MeerHarry L A Janssen
Apr 15, 2014·The New England Journal of Medicine·Nezam AfdhalUNKNOWN ION-2 Investigators
Apr 15, 2014·The New England Journal of Medicine·Nezam AfdhalUNKNOWN ION-1 Investigators
Jul 30, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jane P MessinaEleanor Barnes
Dec 23, 2014·Liver International : Official Journal of the International Association for the Study of the Liver·Tarik Asselah, Patrick Marcellin
Apr 26, 2015·Journal of Hepatology·UNKNOWN European Association for Study of Liver

❮ Previous
Next ❯

Citations

Jan 25, 2016·The Lancet Infectious Diseases·Antonio Rivero-Juárez, Antonio Rivero
Sep 20, 2016·Journal of Hepatology·Jordan J Feld, Graham R Foster
Sep 27, 2016·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu
Nov 1, 2016·Expert Opinion on Drug Metabolism & Toxicology·Francisca Cuenca-LopezAntonio Rivero-Juárez
Mar 7, 2017·Clinical Pharmacology in Drug Development·Justin Chan, Raymond T Chung
Dec 7, 2016·Journal of Medical Virology·Bao Ngoc NguyenMasatoshi Hagiwara
Jun 17, 2016·The Annals of Pharmacotherapy·José A Morales-MolinaAlba Martos-Rosa
Jul 22, 2017·Viral Immunology·Rania A ZayedLobna O Elmessery
Apr 26, 2018·Hemodialysis International·Lorena Puchades Renau, Marina Berenguer
Aug 11, 2018·Clinical and Molecular Hepatology·UNKNOWN Korean Association for the Study of the Liver (KASL)
Nov 1, 2016·Clinical Microbiology Reviews·Eleanor M WilsonShyam Kottilil
May 23, 2019·Clinical Pharmacokinetics·Elise J SmoldersDavid M Burger
Sep 15, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·UNKNOWN AASLD-IDSA HCV Guidance Panel
May 24, 2020·Liver International : Official Journal of the International Association for the Study of the Liver·Betty B YaoTarik Asselah
Oct 1, 2019·The Nurse Practitioner·Renee PozzaTarek Hassanein
Nov 30, 2016·World Journal of Gastroenterology : WJG·Nina WeilerMartin-Walter Welker
Oct 25, 2017·Journal of Nephrology·Sami Aoufi-RabihUNKNOWN On behalf on the Spanish Association of the Liver and the Kidney (AEHR)
Nov 6, 2018·World Journal of Hepatology·Monjur Ahmed
Oct 20, 2018·Applied Biochemistry and Biotechnology·Rasha ShaabanEhab El-Dabaa
Feb 23, 2017·Hepatology International·Seng Gee Lim
Dec 16, 2017·Current Treatment Options in Infectious Diseases·Autumn ZuckermanSusanna Naggie
Aug 16, 2019·World Journal of Gastroenterology : WJG·Massimo Giuseppe ColomboSanjay Hadigal
Feb 7, 2018·Hepatology Communications·Edward J GaneEric Lawitz
Nov 28, 2020·The Journal of Infectious Diseases·Oluwaseun Falade-Nwulia, Mark S Sulkowski
Oct 22, 2019·Lancet·C Wendy SpearmanMark Sonderup
Feb 2, 2017·Deutsches Ärzteblatt International·Stefan Zeuzem
May 4, 2020·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Ming-Lung YuWan-Long Chuang
Jul 6, 2021·World Journal of Clinical Cases·Ratchapong Laiwatthanapaisan, Apichet Sirinawasatien
Jul 25, 2021·Nature Communications·Masahiko AjiroMasatoshi Hagiwara

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.